These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20061166)

  • 21. AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism.
    van Agteren M; Armstrong VW; van Schaik RH; de Fijter H; Hartmann A; Zeier M; Budde K; Kuypers D; Pisarski P; Le Meur Y; van der Werf M; Mamelok RD; Oellerich M; van Gelder T
    Ther Drug Monit; 2008 Aug; 30(4):439-44. PubMed ID: 18641546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M; Deering KL; Slakey DP; Harshaw Q; Arcona S; McCann EL; Rasetto FA; Florman SS
    Transplantation; 2009 Aug; 88(4):514-20. PubMed ID: 19696634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients.
    Prausa SE; Fukuda T; Maseck D; Curtsinger KL; Liu C; Zhang K; Nick TG; Sherbotie JR; Ellis EN; Goebel J; Vinks AA
    Clin Pharmacol Ther; 2009 May; 85(5):495-500. PubMed ID: 19225446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics.
    Parant F; Rivet C; Boulieu R; Gagnieu MC; Dumortier J; Boillot O; Lachaux A
    Ther Drug Monit; 2009 Dec; 31(6):727-33. PubMed ID: 19881404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolates in transplantation.
    Sollinger HW
    Clin Transplant; 2004 Oct; 18(5):485-92. PubMed ID: 15344948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of mycophenolate mofetil suspension in pediatric renal allograft recipients.
    Bunchman T; Navarro M; Broyer M; Sherbotie J; Chavers B; Tönshoff B; Birk P; Lerner G; Lirenman D; Greenbaum L; Walker R; Zimmerhackl LB; Blowey D; Clark G; Ettenger R; Arterburn S; Klamerus K; Fong A; Tang H; Thomas S; Ramos E
    Pediatr Nephrol; 2001 Dec; 16(12):978-84. PubMed ID: 11793083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switching from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients with gastrointestinal complications.
    Barrera-Pulido L; Alamo-Martínez JM; Marín-Gómez LM; Suárez-Artacho G; Bernal-Bellido C; Domínguez-Usero D; Tallón-Aguilar L; Pareja-Ciuró F; Sousa-Martín JM; García-González I; Gómez-Bravo MA
    Transplant Proc; 2009; 41(6):2192-4. PubMed ID: 19715870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.
    Tredger JM; Brown NW; Adams J; Gonde CE; Dhawan A; Rela M; Heaton N
    Liver Transpl; 2004 Apr; 10(4):492-502. PubMed ID: 15048791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
    Gensburger O; Van Schaik RH; Picard N; Le Meur Y; Rousseau A; Woillard JB; Van Gelder T; Marquet P
    Pharmacogenet Genomics; 2010 Sep; 20(9):537-43. PubMed ID: 20679962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
    Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients.
    Molinaro M; Chiarelli LR; Biancone L; Castagneto M; Boschiero L; Pisani F; Sabbatini M; Sandrini S; Arbustini E; Tinelli C; Regazzi M; Schena FP; Segoloni GP
    Drug Metab Pharmacokinet; 2013; 28(2):109-17. PubMed ID: 22892445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium.
    Kamar N; Oufroukhi L; Faure P; Ribes D; Cointault O; Lavayssiere L; Nogier MB; Esposito L; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Oct; 20(10):2231-6. PubMed ID: 16046517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
    Lobach NE; Pollock-Barziv SM; West LJ; Dipchand AI
    J Heart Lung Transplant; 2005 Feb; 24(2):184-9. PubMed ID: 15701435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure.
    Bunnapradist S; Lentine KL; Burroughs TE; Pinsky BW; Hardinger KL; Brennan DC; Schnitzler MA
    Transplantation; 2006 Jul; 82(1):102-7. PubMed ID: 16861948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele.
    Woillard JB; Rerolle JP; Picard N; Rousseau A; Drouet M; Munteanu E; Essig M; Marquet P; Le Meur Y
    Br J Clin Pharmacol; 2010 Jun; 69(6):675-83. PubMed ID: 20565459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
    Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of mycophenolate mofetil for treatment of kidney disease due to congenital urinary tract disorders in children.
    Trachtman H; Christen E; Frank R; Rini J; Palestro C; Perelstein E; Weiss L; Tarapore F; Fortune S; Horowitz J
    Am J Kidney Dis; 2008 Oct; 52(4):706-15. PubMed ID: 18554762
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination effect of mycophenolate mofetil with mizoribine on cell proliferation assays and in a mouse heart transplantation model.
    Shimmura H; Tanabe K; Habiro K; Abe R; Toma H
    Transplantation; 2006 Jul; 82(2):175-9. PubMed ID: 16858279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.